Evaluation of circulating TP53 antigen in the sera of gastric cancer patients: As a tumor marker  by Nasif, Wesam A. et al.
Biomarkers and Genomic Medicine (2013) 5, 175e180Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.j -bgm.comORIGINAL ARTICLEEvaluation of circulating TP53 antigen in
the sera of gastric cancer patients: As a
tumor markerWesam A. Nasif a,b,*, Mohammed H. Mukhtar a,
Hoda M. El-Emshaty c, Talaat A. AL-Bukhari daBiochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
bMolecular Biology Department, Genetic Engineering and Biotechnology Research Institute,
Sadat City University, Sadat City, Cairo, Egypt
cGastroenterology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
dHaematology and Immunology Department, Faculty of Medicine, Umm Al-Qura University,
Makkah, Saudi ArabiaReceived 6 September 2013; received in revised form 4 October 2013; accepted 8 October 2013
Available online 2 December 2013KEYWORDS
enzyme linked
immunosorbent
assay;
gastric cancer;
serum p53 antigen;
tumor marker* Corresponding author. Biochemistr
E-mail addresses: wnasif2003@yah
2214-0247/$36 Copyright ª 2013, Taiw
http://dx.doi.org/10.1016/j.bgm.201Abstract This study deals with the detection of serum p53 antigen concentration by enzyme-
linked immunosorbent assay as a marker for TP53 gene mutation in gastric cancer patients,
correlating it with p53 protein expression detected by immunostaining. The serum concentra-
tion of p53 antigen ranged from 0.28 ng/mL to 0.59 ng/mL [average 0.40  0.08 ng/mL,
(p < 0.001) compared to the normal control (average 0.19  0.11 ng/mL)]. Positive serum
p53 protein concentrations were detected in 29 (36.3%) out of 80 patients, according to adopt-
ing a cut-off value for serum p53 protein concentration of 0.42 ng/mL. This corresponded to a
value of 2 SD (standard deviations) above the mean value from the healthy controls. Expression
of p53 protein was detected in 62.5% (40 of 64) of the nuclei in carcinoma cells from gastric
cancer patients. The average serum p53 antigen concentration in the positive immunostained
cases was 0.42  0.08 ng/mL, with significant elevation compared with that in the negative
immunostained cases (0.36  0.06 ng/mL; p < 0.02). Therefore, serum p53 antigen concentra-
tion would be expected to be a useful marker for gastric cancer.
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The transformation of normal cells to malignant cells is a
multistep process that involves various alterations at the
molecular and genetic levels. These acquired alterations
in DNA often lead to the induction of oncogenes or the
negation of tumor suppressor genes, resulting in malig-
nantly transformed cells.1,2 The wild type TP53 tumor
suppressor gene has a pivotal antimalignant role in
humans and functions as a crucial gate keeper, which
suppresses tumorgenesis through at least two mechanisms
in response to DNA damage, arrest of cell proliferation,
and induction of apoptosis.3,4 However, TP53 is also the
most frequently mutated gene in human cancer, leading
to nonefficient removal of tumor cells and to carcino-
genesis.5 In gastric cancer, the TP53 gene is frequently
mutated and p53 overexpression is observed in w50% of
tumors.6 TP53 gene mutation results in the synthesis of a
mutant protein, which has a longer half-life than that of
the wild type protein and accumulates in transformed
cells.7,8 This finding encourages extensive studies on the
TP53 gene mutations and the increased accumulation of
p53 protein has been shown by both direct sequencing and
immunohistochemistry in a large panel of tumors.9,10
However, both methods require tissue specimens.11
Recently, p53 protein has been measured by enzyme-
linked immunosorbent assay in serum samples from pa-
tients with carcinoma of the colon,12 pancreas13 and
lung,14 and was significantly raised compared with nega-
tive controls. The accumulation of mutant p53 protein in
the nuclei of tumor cells can be released into the extra-
cellular environment. Although tissue p53 estimation is a
well-established procedure and its association with the
invasiveness of the tumor and prognosis has been widely
studied, serum p53 protein estimation has not been
studied adequately.15 Therefore, the serum concentration
of p53 antigen was correlated with alterations of the TP53
gene in gastric carcinoma.
We conducted this study to determine the correlation
between serum p53 antigen and gastric carcinoma, and
toinvestigate whether serum p53 protein concentrations
can be used as markers for TP53 gene alterations.Materials and methods
Samples
Eighty serum samples (54 men and 26 women; mean age:
50.5  12.79 years, age range: 20e79 years) were obtained
preoperatively from patients with gastric cancer. Also,
tissue specimens were obtained from patients during sur-
gery performed in the Gastroenterology Center, Mansoura
University, Egypt. Twenty-five normal serum and gastric
mucosa samples were used as negative controls. Serum
specimens were stored at e70C until analysis. Tissue
specimens were histologically diagnosed by the micro-
scopic examination of hematoxylin-and-eosin-stained sec-
tions according to the International Union Against Cancer
(UICC).Measurement of serum p53 antigen in serum gastric
cancer patients using ELISA
Serum concentrations of the p53 antigen were analyzed by
a p53-mutant-selective ELISA assay kit (Oncogene Science,
Cambridge, UK) according to the manufacturer’s protocol.
Briefly, microtiter wells were precoated with PAb240, a
mouse monoclonal antibody specific for most native
mammalian mutant p53 proteins.16 Aliquots (100 mL) of
serum were added to each well, and were incubated at 4 C
overnight. After washing the wells, 100 mL rabbit polyclonal
reporter antibody, which also recognizes mutant mamma-
lian p53 proteins, was added to each well and was incu-
bated at room temperature for 2 hours. After washing the
wells, 100 mL horseradish-peroxidase-conjugated goat anti-
rabbit IgG was added to each well, and was incubated at
room temperature for 1 hour. After washing again, the
wells were incubated with 100 mL chromogenic substrate
(2,2ʹ-azino-di-3-ethyl-benzthiazoline sulfonate) at room
temperature for 30 minutes. The colored reaction product
was quantified by examining its absorbance at 405 nm using
a spectrophotometer. The concentration of mutant p53
protein in the serum was then determined by comparison
against a standard curve generated from a known concen-
tration of mutant p53 protein (0, 0.25 ng/mL, 0.5 ng/mL,
1 ng/mL, 2 ng/mL and 4 ng/mL). By this approach, this
assay can be seen to have a limit of detection of 0.05 ng/mL
and generate a linear standard curve up to 4.0 ng/mL, with
cross-reactivity with normal p53 according to the manu-
facturer (Oncogenic Science, Cambridge, UK).
Immunohistochemistry
Immunohistochemical localization of p53 antigen was per-
formed on formalin-fixed, paraffin-embedded tissue blocks
that were sectioned at 4-mm thickness, and immunostaining
was performed using an antigen-retrieval system. The de-
waxed sections were rehydrated in descending grades of
ethanol, incubated with 3% H2O2/absolute methanol to
inhibit endogenous peroxidase activity, and heated in
10 mM sodium citrate buffer (pH 6.0). The background was
blocked by nonimmune serum, and the sections were
incubated overnight with monoclonal antibody to p53 (DO-
7) at 4C. The color was developed using a streptavi-
dinebiotin detection kit (DAKO, Glostrup, Denmark) with 3-
amino-9-ethyl carbazol as the chromogen, and the sections
were counterstained with Mayer’s hematoxylin. The posi-
tivity was detected according to the negative control for
each sample (the primary antibody was omitted) and the
positive control (sample known to be positive for p53 an-
tigen). Staining results were interpreted according to the
scheme reported by many authors17 that describes the
diffuse and focal patterns of p53 immunoreactivity,
considering the diffuse pattern representing the mutated
p53 protein and the focal one for the wild type p53 product.
Flow cytometry
DNA ploidy of DNA content of fresh gastric cancer speci-
mens was carried out as described previously.18 Analysis
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Coulter, Hialeah, FL, USA). The amount of cellular DNA was
expressed as DNA index (DI). Cells with a normal diploid
DNA fluorescence distribution were identified relative to
human peripheral blood as the external DNA reference
standard. Following identification of the diploid G0/G1
peak, a DI value of 1.0 indicated diploidy. A tumor sample
was defined as aneuploid when a bimodally separated
population of G1 cells was present and was calculated as
the ratio of the aneuploid G1 peak to the diploid GI peak in
the same sample.Statistical analysis
All statistical analyses were done using SPSS for Windows
version 10.0 and statistical significance was indicated at a
two-sided p value <0.05. Numerical data were expressed as
mean  standard deviation (SD). The levels of markers
were analyzed by analysis of variance. Correlations be-
tween serum p53 antigen markers and clinicopathological
variables data were evaluated by Pearson’s correlation
coefficient. A p value <0.05 was considered significant.Results
Serum p53 antigen concentrations
ELISA was performed to determine the protein concentra-
tion in the sera of gastric cancer patients. The serum con-
centration of p53 protein ranged from 0.28 ng/mL to
0.59 ng/mL and the average was 0.40  0.08 ng/mL. These
concentrations were significantly elevated (p < 0.001)
compared to the normal controls (0.19  0.11 ng/mL).Control stromal NHL
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Figure 1 The cutoff value for serum p53 protein concen-
tration in gastric cancer patients was 0.42 ng/mL, which was 2
standard deviations above the mean concentration of the
normal controls. Therefore, serum p53 protein concentrations
>0.42 ng/mL were considered positive and those <0.42 ng/ml
were considered negative. Positive serum p53 antigen con-
centrations were detected in 29 (36.3%) of 80 gastric cancer
patients. Positivity for serum p53 protein was found in 22
(35.5%) of 62 patients with adenocarcinoma, two (22.2%) of
nine patients with stromal tumor, and five (55.6%) of nine pa-
tients with non-Hodgkin’s lymphoma (NHL).The cut-off value for the serum p53 protein concentra-
tion in gastric cancer patients was 0.42 ng/mL, which was 2
SD above the mean concentration of the normal controls.
Therefore, serum p53 protein concentrations >0.42 ng/mL
were considered as positive and those <0.42 ng/mL were
considered as negative (Fig. 1). Positive serum p53 antigen
concentrations were detected in 29 (36.3%) of 80 gastric
cancer patients. The positivity for serum p53 protein was
found in 22 (35.5%) of 62 patients with adenocarcinoma, in
two (22.2%) of nine patients with stromal tumor, and in five
(55.6%) of nine patients with non-Hodgkin’s lymphoma
(Fig. 1).
The average p53 protein concentration in the adeno-
carcinoma patients was 0.41 ng/mL, 0.39 ng/mL in stromal
tumor, and 0.42 ng/mL in non-Hodgkin’s lymphoma. These
results were significant compared to the normal controls
(p < 0.001) (Table 1, Fig. 1). The mean serum p53 protein
concentration was 0.39 ng/mL in male patients and
0.42 ng/mL in female patients, but the difference was not
statistically significant (p > 0.1). The average p53 level was
0.40 ng/mL in the antrum, 0.39 ng/mL in the corpus, and
0.41 ng/mL in the cardia; however, these results did not
reach statistical significance (p > 0.8). The incidence of
mean p53 concentrations was more frequent in Grade III
(0.43 ng/mL) than Grade I (0.39 ng/mL) and Grade II
(0.38 ng/mL); a significant difference was found only be-
tween Grades II and III (p < 0.02) (Table 1).
Immunostaining for p53 protein expression
Expression of p53 protein was localized immunohis-
tochemically in the nuclei of carcinoma cells in 62.5% (40 of
64) of the tumor specimens examined, using anti-p53
monoclonal antibody DO-7 (Fig. 2). The negative controls
did not show any staining, but positive staining pattern wasTable 1 Correlation of serum concentration of p53 pro-
tein with clinicopathological variables in gastric cancer
patients.
Serum p53 concentrations (ng/mL)
No. Mean  SD Range p
Sex
Male 54 0.39  0.07 0.28e0.56 NS
Female 26 0.42  0.08 0.30e0.58
Histological type
Adenocarcinoma 62 0.41  0.08 0.28e0.59 NS
Stromal tumor 9 0.39  0.05 0.33e0.47
NHL 9 0.42  0.07 0.30e0.51
Site
Antrum 45 0.40  0.07 0.30e0.59 NS
Corpus 22 0.39  0.07 0.30e0.53
Cardia 13 0.41  0.08 0.28e0.53
Tumor grade
I 15 0.39  0.07 0.28e0.55 0.02
II 39 0.38  0.07 0.30e0.53
III 26 0.43  0.09 0.30e0.59
Total 80 0.40  0.08 0.28e0.59
NHL Z non-Hodgkin’s lymphoma; NS Z not significant;
SD Z standard deviation.
Figure 2 Immunohistochemical staining of p53 protein
expression in gastric carcinoma using monoclonal antibody DO-
7 and avidinebiotin peroxidase detection in gastric cancer
tissue showing intracytoplasmic immunoreactivity of p53
(400).
Table 3 Correlation between serum p53 protein concen-
tration and immunostaining in 64 patients with gastric
cancer.
p53 immunostaining
Negativea
No.
Positiveb
No.
Total
No.
Serum p53 protein
Negative 19 22 41
Positive 5 18 23
Total 24 40 64
a Serum p53 protein <0.42 ng/mL.
b Serum p53 protein 0.42 ng/mL.
178 W.A. Nasif et al.classified as diffuse or focal according to the percentage of
stained nuclei. A focal pattern of p53 (<30% stained nuclei)
was identified in 47.5%, whereas a diffuse pattern was
identified in 52.5% of positive immunostained cases.
Correlation between serum p53 protein and
immunostaining
The correlation between serum p53 protein concentration
and immunohistochemical staining for p53 protein was
analyzed in 64 matched cases of gastric cancer (Table 2).
The average serum p53 protein concentration in the posi-
tive immunostained cases was 0.42  0.08 ng/mL and was
significantly higher than in the negative immunostained
cases 0.36  0.06 ng/mL (p < 0.02; Table 2). Furthermore,
positive serum p53 concentrations were found in 18 (45%) of
40 positive immunostained cases, but in only five (20.8%) of
24 negative immunostained cases (p < 0.002). In addition,
serum negative p53 was found in 19 (79.2%) of 24 cases
negative for p53 protein by immunostaining (Table 3).Table 2 Correlation between serum p53 protein concen-
tration and immunostaining for p53 expression and DNA
ploidy pattern.
Serum p53 concentrations (ng/mL)
No. Mean  SD p
p53 protein immunostaining
Negative 24 0.36  0.06 0.02
Positive 40 0.42  0.08
Total 64
DNA ploidy pattern
Diploidy 24 0.39  0.07 NS
Aneuploidy 21 0.40  0.06
Total 45
NS Z not significant; SD Z standard deviation.Positive immunostaining for p53 protein was found in 18
(78.3%) of 23 cases positive for p53 protein in serum and in
22 (53.8%) of 41 cases negative for serum p53 antigen
(Table 3).
Correlation between p53 protein expression and
DNA ploidy pattern
DNA ploidy pattern was determined in 45 cases of gastric
cancer; 46.7% (21 of 45) of gastric cancer specimens
showed DNA aneuploidy. In such cases, the average serum
p53 protein concentration was 0.40  0.06 ng/mL
compared with 0.39  0.07 ng/mL in diploid cases. The
serum concentrations of p53 protein did not correlate
significantly with DNA ploidy (p > 0.2; Table 2). The posi-
tivity for serum p53 was found in 10 (46.7%) of 21 of
aneuploid cases and in only seven (29.2%) of 24 of diploid
cases (p < 0.006). DNA aneuploidy was detected in 10 (58.8
%) of 17 positive cases for serum p53 protein antigen and in
11 (39.3 %) of 28 negative cases for serum p53 protein an-
tigen (p > 0.003) (Table 4). DNA aneuploidy was detected in
15 (60 %) of 25 positive immunostained cases for p53 protein
and in five (33.3%) of 15 negative immunostained cases for
p53 expression (p > 0.001) (Table 4).Discussion
Gastric cancer is a highly prevalent disease associated with
a high rate of mortality. Therefore, there is a need for
improved clinical and biological markers for disease
behavior.19,20 A sensitive and quantitative ELISA technique
has been developed for the measurement of p53 antigen
concentrations in the serum of gastric cancer patients. In
the current study, serum concentrations of p53 antigen
were detected in gastric cancer patients by ELISA and
analyzed as to whether they were correlated with immu-
nostaining for p53 protein and DNA ploidy pattern. To the
best of our knowledge, there have been no previous reports
measuring the concentrations of serum p53 antigen in pa-
tients with gastric cancer.
Serum p53 concentrations in patients with gastric car-
cinoma were significantly higher than those in the healthy
control group (p < 0.001). Positive serum p53 antigen
concentrations >0.42 ng/mL were found in 29 of 80 pa-
tients examined (36.3%). Similar results were reported in
Table 4 Correlation between p53 protein expression and
DNA ploidy pattern in patients with gastric cancer.
DNA ploidy
Diploidy
No.
Aneuploidy
No.
Total
No.
Serum p53 protein
Negative 17 11 28
Positive 7 10 17
Total 24 21 45
IHC for p53 protein
Negative 10 5 15
Positive 10 15 25
Total 20 20 40
IHC Z immunohistochemistry.
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concentrations by ELISA in colon and pancreatic carci-
nomas, in which raised concentrations were detected in
32% of the colon carcinoma12 and in 22.1% of the pancreatic
adenocarcinoma15 cases. Moreover, our patients with pos-
itive serum p53 antigen concentrations were most often
found to have adenocarcinoma (p < 0.001).
In the present study, the incidence of serum p53 antigen
concentrations was more frequently elevated in patients
with Grade III than Grade I and II cancer, and there were
significant differences in concentrations of serum p53 an-
tigen between Grades II and III (p < 0.02). The results
suggest that advanced gastric carcinoma is associated with
abnormal serum p53 protein and that detection of serum
p53 protein reflects important events in gastric carcino-
genesis. Serum p53 protein did not correlate with other
clinicopathological parameters that are consistent with
previous studies.12,15,21
In response to DNA damage or genetic errors, like in
neoplastic tissue, wild type p53 protein accumulation can
be detected as occasionally stained nuclei in contrast to
the diffuse staining pattern that is associated with muta-
tion.17 The present study showed that p53 protein expres-
sion was localized immunohistochemically in the nuclei of
carcinoma cells in 62.5% of the tumor specimens examined.
Focal nuclear staining was detected in 47.5%, whereas
diffuse nuclear p53 staining was detected in 52.5%. Our
data are in agreement with previous reports of 50e70%
staining, regardless of histological type.22,23
Many studies have documented the presence of p53
antibodies in a wide variety of cancer patients, including
gastric cancer patients.3,24 Such antibodies were usually
associated with the accumulation of mutant p53 protein
within the tumor cells.25 Anti-p53 protein antibodies were
detected in 20e32% of gastric cancer patients who were
positive for p53 serum antigen. The presence of serum p53
protein antibodies was thought to be an early marker of
cancer, whereas p53 antigen can be detected during the
progressive stage. Thus, it remains to be elucidated
whether there is a relation between p53 protein antibodies
and p53 antigen in the serum of cancer patients.26,27
However, the presence of such antibodies could accel-
erate the clearance of p53 from serum or interfere with the
ability of the assay to identify p53 by masking the relevantepitopes, thus lowering the detectable levels and causing
false-negative results for the protein. This could partially
explain the somewhat lower percentage of positive serum
p53 cases among carcinomas in this study compared to
positive cases for p53 by immunohistochemistry.12,28,29
Additional confounding factors include the fact that not
all TP53 gene mutations lead to increased p53 protein
levels intracellularly,30 and not all tumors with increased
intracellular p53 levels necessarily release the p53 into the
extracellular environment.14 The mechanism by which TP53
gains access to the extracellular environment is not known.
In the present study, the specificity of serum p53 antigen
was 79.2%. These results are similar to those obtained with
sera from patients with pancreatic carcinomas by Suwa
et al.15 Twenty-two (55%) of 40 cases with positive immu-
nostaining were negative for serum p53 antigen by ELISA
and were considered to be false negatives. The reason for
these false-negative cases may be that not all tumors with
TP53 gene overexpression necessarily release p53 protein
into the bloodstream, or that the presence of p53 protein
antibodies can impair the detection of p53 protein in the
serum.
Five (20.8%) of 24 cases that were negatively immu-
nostained were positive by ELISA and were considered to
be false positives. The false-positive results could have
resulted from underestimation of the p53 protein immu-
nostaining due to heterogeneity of the tumor cells.
Alternatively, they could have arisen from nonspecific
cross-reactions with other serum proteins that have
similar epitopes to p53, or from a stabilization of the p53
protein due to binding with other serum proteins via an
unknown mechanism. However, positive p53 immuno-
stained cases were detected in 18 (78.3%) of 23 patients
positive for serum p53 antigen. Therefore, the serum
concentrations of p53 are expected to be more closely
correlated with p53 antigen immunostaining in tumor
cells.15
In gastric cancer, analysis of DNA ploidy may provide
clinically useful information on diagnostic, therapeutic,
and prognostic aspects.31 In the gastric specimens, aneu-
ploidy was determined only in malignant cases. In four of
the seven samples of ulcerative colitis and in one of the
three adenocarcinoma samples, aneuploidy was found. The
histologically healthy specimens were all diploid.32 In the
present study, aneuploidy was detected in 21 (46.7%) of 45
cases of gastric cancer. Our data were confirmed by the
previous report by Kim and Cho33 that the incidence of
aneuploidy and diploidy was similar (48.8% vs. 51.1%),
which was examined in gastric cancer patients who un-
derwent stomach resection.
In the present study, the serum p53 protein concentra-
tions did not correlate significantly with the ploidy pattern.
Aneuploidy was detected in 10 (58.8%) of 17 cases positive
for serum p53 antigen and in 11 (39.3%) of 28 negative cases
for serum p53 antigen. Positivity for serum p53 antigen was
found more frequently in aneuploid cases (10 of 21, 47.7%)
than in diploid cases (7 of 24 cases, 29.2%) (p > 0.006).
Also, aneuploidy pattern was detected in 60% of cases with
positive immunostaining for p53 protein expression and in
33.3% of negative cases (p > 0.001). These findings could
suggest that, in some cases, mutations in p53 may occur at
a step before tissue invasion. Thus, alteration in p53 may
180 W.A. Nasif et al.be pathogenetic in the evolution of a premalignant to a
malignant state.34
In conclusion, serum p53 antigen concentrations may tell
us about the functional status of the p53 pathway rather
than the presence of gene mutation. Serum assay of p53
protein is noninvasive and easy to perform. Thus, the assay
of serum p53 antigen concentrations by ELISA is expected
to be a useful screening procedure for detecting mutant
p53 gene in gastric cancer. In the future, serum p53 antigen
appears to be a promising new parameter to evaluate the
cellular biology and prognosis of gastric cancer.
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